Kazia Therapeutics Recommandation moyenne
Quel est le Recommandation moyenne de Kazia Therapeutics?
Le Recommandation moyenne de Kazia Therapeutics Limited est 2.00
Quelle est la définition de Recommandation moyenne?
La moyenne recommandée est la moyenne des évaluations des actions par les analystes allant de 1,0 (achat fort) à 5,0 (vente forte).
Mean of recommendations is an average of ratings from different analysts but it should still be used with other research and investment metrics in order to make investment decisions. It is important to understand a firm's entire scale when assimilating ratings. Additionally, analyst recommendations on stocks owned by firms employing them may be seen as potentially biased.
Financial analysts are often employed by mutual and pension funds, hedge funds, securities firms, banks, investment banks, insurance companies, and other businesses, helping these companies or their clients make investment decisions. Financial analysts employed in commercial lending perform "balance sheet analysis," examining the audited financial statements and corollary data in order to assess lending risks. In a stock brokerage house or in an investment bank, they read company financial statements and analyze commodity prices, sales, costs, expenses, and tax rates in order to determine a company's value and project future earnings. In any of these various institutions, the analyst often meets with company officials to gain a better insight into a company's prospects and to determine the company's managerial effectiveness.
Usually, financial analysts study an entire industry, assessing current trends in business practices, products, and industry competition. They must keep abreast of new regulations or policies that may affect the industry, as well as monitor the economy to determine its effect on earnings.
Recommandation moyenne des entreprises dans Health Care secteur sur ASX par rapport à Kazia Therapeutics
Que fait Kazia Therapeutics?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Entreprises avec recommandation moyenne similaire à Kazia Therapeutics
- Cabot Oil & Gas a Recommandation moyenne de 1.96
- Truist a Recommandation moyenne de 1.96
- Delta Air Lines a Recommandation moyenne de 1.96
- Discover Services a Recommandation moyenne de 1.96
- United Micro Electronics a Recommandation moyenne de 1.96
- Tapestry Inc a Recommandation moyenne de 1.97
- Kazia Therapeutics a Recommandation moyenne de 2.00
- Trip.com Ltd a Recommandation moyenne de 2.03
- Sherwin-Williams Co a Recommandation moyenne de 2.03
- Canadian Pacific Kansas City a Recommandation moyenne de 2.03
- Arista Networks Inc a Recommandation moyenne de 2.03
- Anheuser-Busch InBev SA/NV a Recommandation moyenne de 2.03
- Celanese Corp a Recommandation moyenne de 2.04